UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-36457

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		90-0031917
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~10025 Investment Drive~~800 S Gay Street, Suite ~~250~~1610 Knoxville, Tennessee		~~37932~~37929
(Address of principal executive offices)		(Zip Code)

866-594-5999

(Registrant’s telephone number, including area code)

~~Not Applicable~~10025 Investment Drive, Suite 250, Knoxville, TN 37932

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of ~~May 11,~~August 10, 2022, was ~~419,447,119~~419,497,119.

TABLE OF CONTENTS

	Page
PART I - FINANCIAL INFORMATION

Cautionary Note Regarding Forward-Looking Statements	1
Item 1. Financial Statements (unaudited)	2
Condensed Consolidated Balance Sheets	2
Condensed Consolidated Statements of Operations	3
Condensed Consolidated Statements of Comprehensive Loss	4
Condensed Consolidated Statements of Changes in Stockholders’ Deficiency	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3. Quantitative and Qualitative Disclosures About Market Risk	17
Item 4. Controls and Procedures	17

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	1718
Item 1A. Risk Factors	1718
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	1718
Item 3. Defaults Upon Senior Securities	1819
Item 4. Mine Safety Disclosures	1819
Item 5. Other Information	1819
Item 6. Exhibits	1819

SIGNATURES	1920

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations. These statements also express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “predict,” “project,” “should,” “strategy,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date, unless otherwise required by law.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”) (including those described in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2021), and Item 1A of Part II of this Quarterly Report on Form 10-Q for the quarter ended ~~March 31,~~June 30, 2022, and:

	●	Our potential receipt of sales from investigational rose bengal sodium-based drug products PV-10^® and PH-10^®, and/or any other halogenated xanthene-based drug products (if and when approved); and licensing, milestone, royalty, and/or other payments related to these investigational drug products and/or the Company’s liquidation, dissolution, or winding up, or any sale, lease, conveyance, or other disposition of any intellectual property relating to rose bengal sodium-based and other halogenated xanthene-based investigational drug products and/or drug substances,

	●	Our ability to raise additional capital through the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, and/or public offerings of debt or equity securities,

	●	The widespread outbreak of an illness or communicable/infectious disease, such as severe acute respiratory syndrome coronavirus 2, or a public health crisis, could disrupt our business and adversely affect our operations and financial condition, and

	●	~~Recently, many~~Many companies across a variety of sectors have reported and continue to report disruptions, shortages, and other supply chain-related issues. In the biopharmaceutical sector, delays and interruptions in the supply chain have been particularly pronounced. During ~~the first~~this second quarter of 2022, we were able to effectively manage our supply of prescription drug candidates in a manner that avoided any significant interruptions to our clinical programs.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31,			December 31,			June 30,			December 31,
	2022			2021			2022			2021
		(Unaudited)						(Unaudited)
Assets

Current Assets:
Cash and cash equivalents	$	173,614		$	682,984		$	84,274		$	682,984
Restricted cash		2,307,395			2,423,958			1,948,335			2,423,958
Short-term receivables		3,050			5,107			2,744			5,107
Prepaid expenses and other current assets		227,908			329,908			243,394			329,908

Total Current Assets		2,711,967			3,441,957			2,278,747			3,441,957

Equipment and furnishings, less accumulated depreciation of $94,396 and $91,178, respectively		28,618			31,836
Equipment and furnishings, less accumulated depreciation of $97,215 and $91,178, respectively								25,799			31,836
Operating lease right-of-use asset		15,177			39,563			138,863			39,563

Total Assets	$	2,755,762		$	3,513,356		$	2,443,409		$	3,513,356

Liabilities and Stockholders’ Deficiency

Current Liabilities:
Accounts payable	$	1,597,496		$	1,287,459		$	1,894,201		$	1,287,459
Deposit for purchase of Series D-1 Preferred Stock		-			150,000			-			150,000
Unearned grant revenue		2,312,395			2,500,000			1,990,685			2,500,000
Other accrued expenses		2,185,761			2,002,486			2,331,621			2,002,486
Accrued interest		35,856			10,578			68,389			10,578
Accrued interest - related parties		10,044			6,044			14,044			6,044
Notes payable		154,925			238,452			142,693			238,452
Convertible notes payable		1,310,000			1,260,000			1,810,000			1,260,000
Convertible notes payable - related parties		200,000			200,000			200,000			200,000
Operating lease liability		18,203			45,617
Operating lease liability, current portion								42,662			45,617

Total Current Liabilities		7,824,680			7,700,636			8,494,295			7,700,636

Operating lease liability, non-current portion								96,201			-

Total Liabilities								8,590,496			7,700,636

Commitments, contingencies, and litigations (Note 11)		-						-			-
Stockholders’ Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized;
Series D Convertible Preferred Stock; 12,374,000 shares designated; 12,373,247 shares issued and outstanding at June 30, 2022 and December 31, 2021; aggregate liquidation preference of $14,164,889 at June 30, 2022 and December 31, 2021								12,373			12,373
Series D-1 Convertible Preferred Stock; 11,241,000 shares designated; 9,270,860 and 9,218,449 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $106,132,320 and $105,532,804 at June 30, 2022 and December 31, 2021, respectively								9,271			9,219
Preferred stock, value

Stockholders’ Deficiency:
Series D Convertible Preferred Stock; 12,374,000 shares designated; 12,373,247 shares issued and outstanding at March 31, 2022 and December 31, 2021; aggregate liquidation preference of $14,164,889 at March 31, 2022 and December 31, 2021		12,373			12,373
Series D-1 Convertible Preferred Stock; 11,241,000 shares designated; 9,270,860 and 9,218,449 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $106,132,320 and $105,532,804 at March 31, 2022 and December 31, 2021, respectively		9,271			9,219
Preferred stock value
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 shares issued and outstanding at March 31, 2022 and December 31, 2021		419,447			419,447
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 shares issued and outstanding at June 30, 2022 and December 31, 2021								419,447			419,447
Additional paid-in capital		241,590,054			241,440,106			241,590,054			241,440,106
Accumulated other comprehensive loss		(35,183	)		(34,467	)		(35,511	)		(34,467	)
Accumulated deficit		(247,064,880	)		(246,033,958	)		(248,142,721	)		(246,033,958	)

Total Stockholders’ Deficiency		(5,068,918	)		(4,187,280	)		(6,147,087	)		(4,187,280	)

Total Liabilities and Stockholders’ Deficiency	$	2,755,762		$	3,513,356		$	2,443,409		$	3,513,356

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	2022			2021
	For the Three Months Ended						For the Three Months Ended						For the Six Months Ended
	March 31,						June 30,						June 30,
	2022			2021			2022			2021			2022			2021

Grant Revenue	$	187,605		$	-		$	321,710		$	-		$	509,315		$	-

Operating Expenses:
Research and development		671,116			655,144			816,648			602,979			1,487,764			1,258,123
General and administrative		516,547			525,532			583,042			619,038			1,099,589			1,144,570
Total Operating Expenses		1,187,663			1,180,676			1,399,690			1,222,017			2,587,353			2,402,693

Total Operating Loss		(1,000,058	)		(1,180,676	)		(1,077,980	)		(1,222,017	)		(2,078,038	)		(2,402,693	)

Other Income/(Expense):
Research and development tax credit								38,259			32,144			38,259			32,144
Gain from extinguishment								-			63,094			-			63,094
Interest income and interest expense		(30,864	)		(489,274	)		(38,120	)		(452,812	)		(68,984	)		(942,086	)

Total Other Expense, Net		(30,864	)		(489,274	)
Total Other Income/(Expense), Net								139			(357,574	)		(30,725	)		(846,848	)

Net Loss	$	(1,030,922	)	$	(1,669,950	)	$	(1,077,841	)	$	(1,579,591	)	$	(2,108,763	)	$	(3,249,541	)

Basic and Diluted Loss Per Common Share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)		(0.01	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding - Basic and Diluted		419,447,119			402,184,815			419,447,119			403,628,466			419,447,119			402,910,628

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

	2022			2021
	For the Three Months Ended						For the Three Months Ended						For the Six Months Ended
	March 31,						June 30,						June 30,
	2022			2021			2022			2021			2022			2021

Net Loss	$	(1,030,922	)	$	(1,669,950	)	$	(1,077,841	)	$	(1,579,591	)	$	(2,108,763	)	$	(3,249,541	)
Other Comprehensive Loss:
Foreign currency translation adjustments		(716	)		837			(328	)		(1,121	)		(1,044	)		(284	)
Total Comprehensive Loss	$	(1,031,638	)	$	(1,669,113	)	$	(1,078,169	)	$	(1,580,712	)	$	(2,109,807	)	$	(3,249,825	)

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY

(Unaudited)

FOR THE ~~THREE~~SIX MONTHS ENDED ~~MARCH 31,~~JUNE 30, 2022


	Preferred Stock				Preferred Stock				Preferred Stock								Additional		Accumulated Other										Preferred Stock				Preferred Stock								Additional		Accumulated Other
	Series B				Series D				Series D-1				Common Stock				Paid-In		Comprehensive			Accumulated							Series D				Series D-1				Common Stock				Paid-In		Comprehensive			Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total				Shares		Amount		Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total

Balance at January 1, 2022		-		-		12,373,247	$	12,373		9,218,449	$	9,219		419,447,119	$	419,447	$	241,440,106	$	(34,467	)	$	(246,033,958	)	$	(4,187,280	)	-		12,373,247	$	12,373		9,218,449	$	9,219		419,447,119	$	419,447	$	241,440,106	$	(34,467	)	$	(246,033,958	)	$	(4,187,280	)

Series D-1 Preferred Stock issued for cash		-		-		-		-		52,411		52		-		-		149,948		-			-			150,000
Common stock issued upon exercise of warrants						-		-		-		-		-
Common stock issued upon exercise of warrants, shares
Common stock
Common stock, shares
Warrants
Conversion of PRH Notes to Series D Preferred Stock
Conversion of PRH Notes to Series D Preferred Stock, shares
Conversion of PRH Notes to Series D-1 Preferred Stock
Conversion of PRH Notes to Series D-1 Preferred Stock, shares

Series D-1 Preferred Stock issued for cash																														-		-		52,411		52		-		-		149,948		-			-			150,000
Comprehensive loss:		-		-												-										-
Net loss						-		-		-		-		-		-		-		-			(1,030,922	)		(1,030,922	)	-		-		-		-		-		-		-		-		-			(1,030,922	)		(1,030,922	)
Other comprehensive loss						-		-		-		-		-		-		-		(716	)		-			(716	)			-		-		-		-		-		-		-		(716	)		-			(716	)

Balance at March 31, 2022		-		-		12,373,247	$	12,373		9,270,860	$	9,271		419,447,119	$	419,447	$	241,590,054	$	(35,183	)	$	(247,064,880	)	$	(5,068,918	)	-		12,373,247	$	12,373		9,270,860	$	9,271		419,447,119	$	419,447	$	241,590,054	$	(35,183	)	$	(247,064,880	)	$	(5,068,918	)

Comprehensive loss:
Net loss																												-		-		-		-		-		-		-		-		-			(1,077,841	)		(1,077,841	)
Other comprehensive income																														-		-		-		-		-		-		-		(328	)		-			(328	)

Balance at June 30, 2022																												-		12,373,247	$	12,373		9,270,860	$	9,271		419,447,119	$	419,447	$	241,590,054	$	(35,511	)	$	(248,142,721	)	$	(6,147,087	)

FOR THE ~~THREE~~SIX MONTHS ENDED ~~MARCH 31,~~JUNE 30, 2021

																													Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total
	Preferred Stock				Preferred Stock				Preferred Stock								Additional		Accumulated Other									Preferred Stock				Preferred Stock				Preferred Stock								Additional		Accumulated Other
	Series B				Series D				Series D-1				Common Stock				Paid-In		Comprehensive			Accumulated						Series B				Series D				Series D-1				Common Stock				Paid-In		Comprehensive			Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total

Balance at January 1, 2021		100	$	-		-		-		-		-		398,807,037	$	398,808	$	209,923,347	$	(34,097	)	$	(240,494,415	)	$	(30,206,357	)		100		-		-		-		-		-		398,807,037	$	398,808	$	209,923,347	$	(34,097	)	$	(240,494,415	)	$	(30,206,357	)

Common stock issued upon exercise of warrants		-		-		-		-		-		-		4,500,000		4,500		235,350		-			-			239,850			-		-		-		-		-		-		4,500,000		4,500		235,350		-			-			239,850
Stock-based compensation:
Common Stock		-		-										250,000		250		19,500		-			-			19,750
Common stock																													-		-		-		-		-		-		250,000		250		19,500		-			-			19,750
Comprehensive loss:																-
Net loss		-		-		-		-		-		-		-		-		-		-			(1,669,950	)		(1,669,950	)		-		-		-		-		-		-		-		-		-		-			(1,669,950	)		(1,669,950	)
Other comprehensive loss		-		-										-		-		-		837			-			837			-		-		-		-		-		-		-		-		-		837			-			837

Balance at March 31, 2021		100	$	-		-		-		-		-		403,557,037	$	403,558	$	210,178,197	$	(33,260	)	$	(242,164,365	)	$	(31,615,870	)		100		-		-		-		-		-		403,557,037	$	403,558	$	210,178,197	$	(33,260	)	$	(242,164,365	)	$	(31,615,870	)
Beginning balance, value																													100		-		-		-		-		-		403,557,037		403,558		210,178,197		(33,260	)		(242,164,365	)		(31,615,870	)

Common stock issued upon exercise of warrants																													-		-		-		-		-		-		200,000		200		10,460		-			-			10,660
Stock-based compensation:
Common stock																													-		-		-		-		-		-		25,000		25		1,650		-			-			1,675
Warrants																													-		-		-		-		-		-		-		-		488		-			-			488
Conversion of PRH Notes to Series D Preferred Stock																													-		-		12,373,247		12,373		-		-		-		-		3,528,849		-			-			3,541,222
Conversion of PRH Notes to Series D-1 Preferred Stock																													-		-		-		-		9,440,594		9,441		-		-		27,022,417		-			-			27,031,858
Comprehensive loss:
Net loss																													-		-		-		-		-		-		-		-		-		-			(1,579,591	)		(1,579,591	)
Net income (loss)																													-		-		-		-		-		-		-		-		-		-			(1,579,591	)		(1,579,591	)
Other comprehensive income																													-		-		-		-		-		-		-		-		-		(1,121	)		-			(1,121	)
Other comprehensive income (loss)																													-		-		-		-		-		-		-		-		-		(1,121	)		-			(1,121	)

Balance at June 30, 2021																													100	$	-		12,373,247	$	12,373		9,440,594	$	9,441		403,782,037	$	403,783	$	240,742,061	$	(34,381	)	$	(243,743,959	)	$	(2,610,682	)

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	For the Six Months Ended
	June 30,
	2022			2021

Cash Flows From Operating Activities:
Net loss	$	(2,108,763	)	$	(3,249,541	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		-			21,913
Non-cash lease expense		31,142			40,012
Depreciation		6,037			6,432
Gain on forgiveness of PPP Loan and interest		-			(63,094	)
Changes in operating assets and liabilities
Short term receivables		2,363			(1,632	)
Prepaid expenses and other current assets		143,940			123,230
Accounts payable - trade		606,742			252,254
Unearned grant revenue		(509,315	)		-
Other accrued expenses		329,135			152,786
Operating lease liability		(37,196	)		(42,191	)
Accrued interest expense		65,811			940,212

Net Cash Used In Operating Activities		(1,470,104	)		(1,819,619	)

Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable		550,000			1,700,000
Repayment of short-term note payable		(153,185	)		(95,387	)
Note Payable		-			(85,398)
Proceeds from exercise of warrants		-			250,510
Net Cash Provided By Financing Activities		396,815			1,769,725

Effect of exchange rates on cash, cash equivalents, and restricted cash		(1,044	)		70

Net Decrease In Cash, Cash Equivalents, and Restricted Cash		(1,074,333	)		(49,824	)

Cash, Cash Equivalents, and Restricted Cash, Beginning of Period		3,106,942			97,231

Cash, Cash Equivalents, and Restricted Cash, End of Period	$	2,032,609		$	47,407

Cash, cash equivalents and restricted cash consisted of the following:
Cash and cash equivalents	$	84,274		$	47,407
Restricted cash		1,948,335			-
	$	2,032,609		$	47,407

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	$	(57,426	)	$	(309,710	)
Deposit applied for purchase of Series D-1 Preferred Stock	$	(150,000	)	$	-
Conversion of non-amended 2017 Notes to Series D Preferred Stock	$	-		$	3,541,222
Conversion of amended 2017 Notes and 2020 Notes to Series D-1 Preferred Stock	$	-		$	27,031,858
Right-of-use assets obtained in exchange for operating lease liabilities	$	130,422		$	-

2022 2021
For the Three Months Ended
March 31,
2022 2021
Cash Flows From Operating Activities:
Net loss $ (1,030,922 ) $ (1,669,950 )
Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation - 19,750
Non-cash lease expense 24,386 20,006
Depreciation 3,218 3,216
Changes in operating assets and liabilities
Short term receivables 2,143 (515 )
Prepaid expenses 101,964 45,822
Accounts payable 309,732 (10,927 )
Unearned grant revenue (187,605 ) -
Other accrued expenses 183,001 12,252
Operating lease liability (27,414 ) (21,096 )
Accrued interest expense 29,278 487,962

Net Cash Used In Operating Activities (592,219 ) (1,113,480 )

Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable

50,000

1,200,000

Repayment of short-term note payable (83,527 ) (74,417 )
Proceeds from exercise of warrants - 239,850
Net Cash (Used In) Provided By Financing Activities (33,527 ) 1,365,433

Effect of exchange rates on cash, cash equivalents, and restricted cash (187 ) 587

Net (Decrease) Increase In Cash, Cash Equivalents, and Restricted Cash (625,933 ) 252,540

Cash, Cash Equivalents, and Restricted Cash, Beginning of Period 3,106,942 97,231

Cash, Cash Equivalents, and Restricted Cash, End of Period $ 2,481,009 $ 349,771

Cash, cash equivalents and restricted cash consisted of the following:
Cash and cash equivalents $ 173,614 $ 349,771
Restricted cash 2,307,395 -
$ 2,481,009 $ 349,771

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest $ - $ -
Income taxes $ - $ -

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Business Organization, Nature of Operations and Basis of Presentation

Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or ~~the “Company”~~“the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of small molecules called halogenated xanthenes (“HXs”) ~~that is~~, a class entirely owned by the Company.

Our lead HX molecule is named rose bengal sodium (“RBS”). The Company has established a multi-step approach using quality-by-design principles for synthesizing and manufacturing pharmaceutical-grade RBS by current good manufacturing practice (“cGMP”) and under the guidelines of The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. A second ~~synthesized~~ HX molecule ishas been synthesized, 4,5,6,7-tetrabromo-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenz- ofuran-1,9′-xanthen]-3-one.

	●	Oncology: PV-10^®, an investigational cancer immunotherapy administered by intralesional (“IL”) injection and an injectable formulation of cGMP RBS, is undergoing clinical study for adult solid tumor cancers, such as melanoma and gastrointestinal (“GI”) tumors, including hepatocellular carcinoma (“HCC”), colorectal cancer metastatic to the liver (“mCRC”), neuroendocrine tumors (“NET”) metastatic to the liver (“mNET”), and uveal melanoma metastatic to the liver (“mUM”), among others. Orphan drug designation (“ODD”) status was granted to PV-10 by the U.S. Food and Drug Administration (the “FDA”) for metastatic melanoma in 2006, HCC in 2011, and ocular melanoma (including uveal melanoma) in 2019.cancers. Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor ~~cancers, such as head and neck, breast, colorectal, and testicular~~ cancers.~~In vivo~~ ~~data of a colorectal tumor murine model that continuously promotes abnormal cell proliferation and transformation into cancer indicate increased survival in both prophylactic and therapeutic settings.~~

	●	Pediatric Oncology: IL PV-10 is undergoing preclinical study for pediatric solid tumor ~~cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). ODD status was granted to PV-10 by the FDA for neuroblastoma in 2018.~~cancers.

	●	Hematology: Oral formulations of cGMP RBS are undergoing preclinical study for refractory and relapsed pediatric blood cancers (including leukemias).~~In vivo~~ ~~data of an acute lymphoblastic leukemia murine model indicated increased survival.~~

	●	Virology: Systemic administration of formulations of cGMP RBS are undergoing preclinical study for the novel strain of coronavirus (“CoV”): severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”).~~In silico~~ ~~data indicate docking-based binding affinity to SARS-CoV-2’s main protease, spike protein, and different variants of the spike protein.~~ ~~In vitro~~ ~~data indicate activity against SARS-CoV-2 in African green monkey kidney cell (Vero) and human lung epithelial cell (Calu-3) models, and synergistic activity with remdesivir in a Vero cell model.~~

	●	Microbiology: Different formulations of cGMP RBS are undergoing preclinical study as potential treatments for multi-drug resistant (“MDR”) ~~bacteria, such as gram-positive and gram-negative.~~ ~~In vitro~~ ~~data indicate activity against a battery of gram-positive bacteria, including MDR strains, under fluorescent, LED, and natural light, and against gram-positive bacterial biofilms.~~bacteria.

	●	Ophthalmology: Topical formulations of cGMP RBS are undergoing preclinical study as potential treatments for diseases and disorders of the ~~eye, such as infectious keratitis.~~eye.

	●	Dermatology: PH-10^®, an investigational immune-dermatology agent administered as a topical formulation of cGMP RBS, is undergoing monotherapy clinical study ~~and~~as well as preclinical study as a monotherapy and in combination therapy with approved drugs for inflammatory ~~dermatoses (including psoriasis and atopic dermatitis).~~dermatoses.

	●	Animal Health: Different formulations of cGMP RBS are undergoing development as potential treatments for animal cancers and dermatological disorders.

To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended ~~March 31,~~June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

SARS-CoV-2 was ~~reportedly~~ first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at ~~March 31,~~June 30, 2022.

The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.

2. Liquidity and Going Concern

The Company’s cash, cash equivalents, and restricted cash were $~~2,481,009~~ 2,032,609at ~~March 31,~~June 30, 2022 which includes ~~the~~ $~~2,307,395~~ 1,948,335of restricted cash resulting from a grant received from the State of Tennessee. The Company’s working capital deficiency was $~~5,112,713~~6,215,548 and $4,258,679 as of ~~March 31,~~June 30, 2022 and December 31, 2021, respectively. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital.

The Company plans to access capital resources through possible public or private equity offerings, including the 2021 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due.

The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

3. SignificantAccounting Policies

Since the date the Company’s December 31, 2021 consolidated financial statements were issued in its 2021 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

Recently Adopted Accounting Standards

In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance is effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its condensed consolidated financial statements.

On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this standard on January 1, 2022 and it did not have a material effect on its condensed consolidated financial statements.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of ~~March 31,~~June 30, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $0 and $42,594., respectively.

Restricted Cash

Restricted cash consists of a grant award of $2,500,000 received in cash from the State of Tennessee less expenses and deposits to vendors in the amount of $~~192,605~~551,665. See Note 10. Grants.

Cash Concentrations

Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of ~~March 31,~~June 30, 2022 and December 31, 2021, the Company had cash, cash ~~equivalent,~~equivalents, and restricted cash balances in excess of FDIC insurance limits of $~~2,231,009~~1,782,609 and $2,856,942, respectively.

Reclassifications

Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.

Basic and Diluted Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares


	March 31,		March 31,		June 30,		June 30,
	2022		2021		2022		2021
Warrants		512,500		82,764,164		512,500		82,589,164
Options		3,625,000		4,800,000		3,425,000		4,800,000
Convertible preferred stock		105,081,847		65,666		105,081,847		106,778,757
2021 unsecured convertible notes		5,436,408		-		7,311,088		-

Total potentially dilutive shares		114,655,755		87,629,830		116,330,435		194,167,921

4. Other Accrued Expenses

The following table summarizes the other accrued expenses at ~~March 31,~~June 30, 2022 and December 31, 2021:

Schedule of Other Accrued Expenses


	March 31, 2022		December 31, 2021		June 30, 2022		December 31, 2021
Accrued payroll and taxes	$	244,349	$	174,533	$	259,008	$	174,533
Accrued vacation		50,859		42,871		56,356		42,871
Accrued directors’ fees		1,656,839		1,560,589		1,753,089		1,560,589
Accrued other expenses		233,714		224,493		263,168		224,493
Total Other Accrued Expenses	$	2,185,761	$	2,002,486	$	2,331,621	$	2,002,486

5. Convertible Notes Payable

2021 Financing

Schedule of Convertible Notes Payable

Non-Related Party Related Party
Face Amount Face Amount Total
Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000

Issued 50,000 - 50,000

Balance as of March 31, 2022 $ 1,310,000 $ 200,000 $ 1,510,000


	Non-Related Party		Related Party
	Face Amount		Face Amount		Total
Balance as of January 1, 2022	$	1,260,000	$	200,000	$	1,460,000

Issued		50,000		-		50,000

Balance as of March 31, 2022	$	1,310,000	$	200,000	$	1,510,000

Beginning Balance	$	1,310,000	$	200,000	$	1,510,000
Issued		500,000		-		500,000

Balance as of June 30, 2022	$	1,810,000	$	200,000	$	2,010,000
Ending Balance	$	1,810,000	$	200,000	$	2,010,000

For further details on the terms of the 2021 Notes, refer to our Form 10-K as filed with the SEC on March 29, 2022.

As of ~~March 31,~~June 30, 2022, the Company had received 2021 Notes proceeds of $~~1,510,000~~2,010,000, of which $200,000 is from a related party investor ~~(an officer~~(a Company officer).

Subsequent to June 30, 2022, the Company received 2021 Notes proceeds of ~~the Company)~~$225,000 from a related party investor (a Company director). See Note 12. Subsequent Events.

6. Notes Payable

The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of ~~March 31,~~June 30, 2022 and December 31, 2021, the balance of the note payable was $~~154,925~~142,693 and $238,452, respectively.

7. Related Party Transactions

During the three months ended ~~March 31,~~June 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $42,400and $~~84,800~~42,400, respectively, for services rendered. Director fees for Mr. Horowitz for the three months ended ~~March 31,~~June 30, 2022 and 2021 were $18,750and $18,750, respectively.

During the six months ended June 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $84,800 and $127,200, respectively, for services rendered. Director fees for Mr. Horowitz for the six months ended June 30, 2022 and 2021 were $37,500 and $37,500, respectively.

Accrued director fees for Mr. Horowitz as of ~~March 31,~~June 30, 2022 and December 31, 2021 were $~~300,000~~ 318,750and $281,250, respectively. Total amount owed to Capital Strategists for consulting fees as of ~~March 31,~~June 30, 2022 and December 31, 2021 were $169,600 and $127,200., respectively. Mr. Horowitz serves as both ~~COO~~Chief Operating Officer (“COO”) and a ~~Director, of the Company.~~Company director.

See Note 5 for details of other related party transactions.

Director fees during the three months ended ~~March 31,~~June 30, 2022 and 2021 were $96,250and $96,250, respectively. Director fees during the six months ended June 30, 2022 and 2021 were $192,500 and $192,500, respectively. Accrued directors’ fees as of ~~March 31,~~June 30, 2022 and December 31, 2021 were $~~1,656,839~~ 1,753,089and $1,560,589, respectively.

8. Stockholders’ Deficiency

Preferred Stock

During the ~~three~~six months ended ~~March 31,~~June 30, 2022, the Company issued 52,411shares of restricted Series D-1 Convertible Preferred Stock in exchange for an investment of $150,000from a non-related ~~party investor.~~party.

Annual Stockholder Meeting Proposals

The Company held its annual meeting of stockholders on June 22, 2022. As proposal number 4, stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board’s recommendation. As proposal number 5, the Company’s stockholders also authorized the Board, given the stockholders’ approval of proposal number 4, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. The Board has not acted on these stockholder authorizations as of the filing date.

9. Leases

The Company ~~currently leases~~leased 4,500square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five yearsending on June 30, ~~2022~~.2022. Payments ~~are~~were approximately $6,100per ~~month.~~

~~On February 23, 2022,~~month due to the Company ~~negotiated~~negotiating a continued reduced rent from January 1, 2022 through June 30, 2022.

On June 30, 2022, the lease expired and was not renewed. On June 18, 2022, the Company moved into 2,700 square feet of leased corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of three years ending June 30, 2025. The monthly base rent ranges from $4,053 to $4,278 over the ~~amount of $6,100~~ ~~per month.~~term on the lease.

Total operating lease expense for the three months ended ~~March 31,~~June 30, 2022 was $~~14,959~~23,092, of which, $~~9,973~~ 15,395was included within research and development and $~~4,986~~ 7,697was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended ~~March 31,~~June 30, 2021 was $~~24,762~~23,044, of which, $~~16,508~~ 15,363was included within research and development and $~~8,254~~ 7,681 was included within general and administrative expenses on the condensed consolidated statement of operations.

Total operating lease expense for the six months ended June 30, 2022 was $38,051, of which, $25,367 was included within research and development and $12,684 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the six months ended June 30, 2021 was $47,806, of which, $31,871 was included within research and development and $15,935was included within general and administrative expenses on the condensed consolidated statement of operations.

A summary of the Company’s right-of-use assets and liabilities is as follows:

Schedule of Right-of-use Assets and Liabilities

For The Three Months Ended
March 31,
2022 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases $ 18,447 $ 23,831

Right-of-use assets obtained in exchange for lease obligations:
Operating leases $ - $ -

Weighted Average Remaining Lease Term
Operating leases 3 months 1 year 3 months

Weighted Average Discount Rate
Operating leases 8.0 % 8.0 %

	For The Six Months Ended
	June 30,
	2022			2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	$	38,625		$	45,784

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	151,693		$	-

Weighted Average Remaining Lease Term
Operating leases		3 years			1 year

Weighted Average Discount Rate
Operating leases		5% - 8.0	%		8.0	%

Future minimum payments under the Company’s non-cancellable lease obligations as of ~~March 31,~~June 30, 2022 were as follows:

Schedule of Future Minimum Payments Under Non-cancellable Lease


Years	Amount			Amount
2022	$	18,447		$	24,318
2023					49,311
2024					50,663
2025					25,669
Total future minimum lease payments		18,447			149,961
Less: amount representing imputed interest		(234	)		11,098
Total	$	18,203		$	138,863

10. Grants

On October 25, 2021, the Company received a grant award of $2,500,000 from the State of Tennessee for the study of animal cancers and dermatological disorders for the period October 15, 2021 to June 30, 2022. As of ~~March 31,~~June 30, 2022, ~~the grant award of~~ $~~2,312,395~~1,990,685 ishas been recorded as unearned grant revenue liability on the accompanying condensed consolidated balance sheets. The Company recorded $~~187,605~~509,315 of grant revenue during the ~~three~~six months ended ~~March 31,~~June 30, 2022. The grant was pre-funded; therefore, the funds do not need to be used in full by June 30, 2022.

11. Commitments, Contingencies and Litigation

The Company may, from time to time, be involved in litigation arising infrom the ordinary course of business and/or ~~which~~that may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

12. Subsequent Events

The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.

~~Subsequent to March 31, 2022, the Company entered into a 2021 Note with a non-related party investor in the aggregate principal amount of $500,000~~ ~~in connection with a 2021 Loan received by the Company for the same amount.~~Convertible Notes Payable

Subsequent to ~~March 31,~~June 30, 2022, the Company ~~announced it has added Aru Narendran, MD, PhD at~~received 2021 Notes proceeds of $225,000 from a related party investor (a Company director).

Common Stock

Subsequent to June 30, 2022, the ~~University~~Company issued an aggregate of ~~Calgary~~25,000 shares of immediately vested restricted common stock to a consultant with a grant date value of $1,500 for services.

Subsequent to June 30, 2022, the ~~Scientific Advisory Board.~~Company issued an aggregate of 25,000 shares of immediately vested restricted common stock to an employee with a grant date value of $1,500 as an award.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited condensed financial statements and our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022 (“2021 Form 10-K”), which includes additional information about our critical accounting policies and practices and risk factors. Historical results and percentage relationships set forth in the consolidated statement of operations, including trends which might appear, are not necessarily indicative of future operations.

~~Overview~~

Provectus is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, based on a class of small molecules called HXs that is entirely owned by the Company. The Company’s lead HX molecule is cGMP RBS.

Components of Operating Results

Grant Revenue

Grant income is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as unearned grant revenue and recognized as other income when qualifying costs are incurred.

Research and Development Expenses

A large component of our total operating expenses is the Company’s investment in research and development activities, including the clinical development of our product candidates. Research and development expenses represent costs incurred to conduct research and undertake clinical trials to develop our drug product candidates. These expenses consist primarily of:

	●	Costs of conducting clinical trials, including amounts paid to clinical centers, clinical research organizations and consultants, among others;
	●	Salaries and related expenses for personnel, including stock-based compensation expense;
	●	Other outside service costs including cost of contract manufacturing;
	●	The costs of supplies and reagents; and,
	●	Occupancy and depreciation charges.

We expense research and development costs as incurred.

Research and development activities are central to our business model. We expect our research and development expenses to increase in the future as we advance our existing product candidates through clinical trials and pursue their regulatory approval. Undertaking clinical development and pursuing regulatory approval are both costly and time-consuming activities. As a result of known and unknown uncertainties, we are unable to determine the duration and completion costs of our research and development activities, or if, when, and to what extent we will generate revenue from any subsequent commercialization and sale of our drug product candidates.

General and Administrative Expenses

General and administrative expense consists primarily of salaries, stock-based compensation expense and other related costs for personnel in executive, finance, accounting, business development, legal, information technology and corporate communication functions. Other costs include facility costs not otherwise included in research and development expense, insurance, and professional fees for legal, patent and accounting services.

Results of Operations

Comparison of the Three Months Ended ~~March 31,~~June 30, 2022 and ~~March 31,~~June 30, 2021

Overview

Total operating expenses were ~~$1,187,663~~$1,399,690 for the three months ended ~~March 31,~~June 30, 2022, an increase of ~~$6,987~~$177,673 or ~~0.6%~~14.5% compared to the three months ended ~~March 31,~~June 30, 2021. The increase was driven primarily by (i) increased clinical trial cost, (ii) higher insurance costs and (iii) higher ~~payroll and taxes,~~professional fees, partially offset by (iv) lower legal and litigation ~~fees and (v) lower rent and utilities cost.~~fees. Net loss for the three months ended ~~March 31,~~June 30, 2022 was ~~$1,030,922,~~$1,077,841, a decrease of ~~$639,028~~$501,750 or ~~38.3%~~31.8% which was primarily attributable to lower interest expense costs incurred in connection with the 2017 and 2020 Notes which converted to preferred stock on June 20, 2021 and the recognition of grant revenue in the amount of ~~$187,605.~~$321,710.

	For the Three Months Ended												For the Three Months Ended
	March 31,												June 30,
	2022			2021			Increase/(Decrease)			% Change			2022			2021			Increase/(Decrease)			% Change

Grant Revenue	$	187,605		$	-		$	187,605			0.0	%	$	321,710		$	-		$	321,710			0.0	%

Operating Expenses:
Research and development		671,116			655,144			15,972			2.4	%		816,648			602,979			213,669			35.4	%
General and administrative		516,547			525,532			(8,985	)		-1.7	%		583,042			619,038			(35,996	)		-5.8	%
Total Operating Expenses		1,187,663			1,180,676			6,987			0.6	%		1,399,690			1,222,017			177,673			14.5	%

Total Operating Loss		(1,000,058	)		(1,180,676	)		180,618			-15.3	%		(1,077,980	)		(1,222,017	)		144,037			-11.8	%

Other Income/(Expense):
Research and development tax credit														38,259			32,144			6,115			19.0	%
Gain from extinguishment														-			63,094			(63,094	)		-100.0	%
Interest income and interest expense		(30,864	)		(489,274	)		458,410			-93.7	%		(38,120	)		(452,812	)		414,692			-91.6	%

Total Other Expense, Net		(30,864	)		(489,274	)		458,410			-93.7	%
Total Other Income/ (Expense), Net														139			(357,574	)		357,713			-100.0	%

Net Loss	$	(1,030,922	)	$	(1,669,950	)	$	639,028			-38.3	%	$	(1,077,841	)	$	(1,579,591	)	$	501,750			-31.8	%

Grant Revenue

For the 3three months ended ~~March 31,~~June 30, 2022 and 2021, there was ~~$187,605~~$321,710 and $0, respectively, of grant revenue recognized related to qualifying expenses that were incurred and included within research and development on the condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses were ~~$671,116~~$816,648 for the three months ended ~~March 31,~~June 30, 2022, an increase of ~~$15,972~~$213,669 or ~~2.4%~~35.4% compared to ~~$655,144~~$602,979 for the three months ended ~~March 31,~~June 30, 2021. The increase was primarily due to (i) increased cost on clinical trials due to increased recruitment and treatment in clinical trials, and (ii) higher insurance cost.

	For the Three Months Ended
	June 30,
	2022		2021		Increase/(Decrease)			% Change
Operating Expenses:
Research and development:
Clinical trial and research expenses	$	674,294	$	465,627	$	208,667			44.8	%
Depreciation/amortization		1,765		2,162		(397	)		-18.4	%
Insurance		57,367		51,393		5,974			11.6	%
Payroll and taxes		67,360		67,706		(346	)		-0.5	%
Rent and utilities		15,862		16,091		(229	)		-1.4	%
Total research and development	$	816,648	$	602,979	$	213,669			35.4	%

General and Administrative Expenses

General and administrative expenses were $583,042 for the three months ended June 30, 2022, a decrease of $35,996 or 5.8% compared to $619,038 for the three months ended June 30, 2021. The decrease was primarily due to (i) lower legal fees relating to patents, partially offset by (ii) higher professional fees, and (iii) increased other general and administration expenses.

	For the Three Months Ended
	June 30,
	2022			2021		Increase/(Decrease)			% Change
Operating Expenses:
General and administrative:
Depreciation	$	1,055		$	1,055	$	-			0.0	%
Directors fees		96,250			96,250		-			0.0	%
Insurance		44,672			42,262		2,410			5.7	%
Legal and litigation		126,087			216,723		(90,636	)		-41.8	%
Other general and administrative cost		34,476			15,583		18,893			121.2	%
Payroll and taxes		63,575			62,540		1,035			1.7	%
Professional fees		208,678			172,759		35,919			20.8	%
Rent and utilities		8,267			8,219		48			0.6	%
Foreign currency translation		(18	)		3,647		(3,665	)		-100.5	%
Total general and administrative	$	583,042		$	619,038	$	(35,996	)		-5.8	%

Other Income/(Expense)

Other income/(expense) decreased by $357,713 from ($357,574) for the three months ended June 30, 2021 to $139 for the three months ended June 30, 2022. The decrease was due to the lower interest expense costs incurred in connection with the 2017 and 2020 Notes which converted to preferred stock on June 20, 2021, offset by the gain from extinguishment of debt in 2021 relating to the PPP loan forgiveness.

	For the Three Months Ended
	June 30,
	2022			2021			Increase/(Decrease)			% Change
Other Income/(Expense):
Research and development tax credit	$	38,259		$	32,144		$	6,115			19.0	%
Gain from extinguishment		-			63,094			(63,094	)		-100.0	%
Interest income and interest expense		(38,120	)		(452,812	)		414,692			-91.6	%
Total Other Income/(Expenses), Net	$	139		$	(357,574	)	$	357,713			-100.0	%

Comparison of the Six Months Ended June 30, 2022 and June 30, 2021

Overview

Total operating expenses were $2,587,353 for the six months ended June 30, 2022, an increase of $184,660 or 7.7% compared to the six months ended June 30, 2021. The increase was driven primarily by (i) increased clinical trial cost, (ii) higher insurance costs and (iii) higher professional fees, partially offset by (iv) lower legal and litigation fees, and (v) lower rent and utility expense. Net loss for the six months ended June 30, 2022 was $2,108,763, a decrease of $1,140,778 or 35.1% which was primarily attributable to lower interest expense costs incurred in connection with the 2017 and 2020 Notes which converted to preferred stock on June 20, 2021 and the recognition of grant revenue in the amount of $509,315.

	For the Six Months Ended
	June 30,
	2022			2021			Increase/(Decrease)			% Change

Grant Revenue	$	509,315		$	-		$	509,315			0.0	%

Operating Expenses:
Research and development		1,487,764			1,258,123			229,641			18.3	%
General and administrative		1,099,589			1,144,570			(44,981	)		-3.9	%
Total Operating Expenses		2,587,353			2,402,693			184,660			7.7	%

Total Operating Loss		(2,078,038	)		(2,402,693	)		324,655			-13.5	%

Other Income/(Expense):
Research and development tax credit		38,259			32,144			6,115			19.0	%
Gain from extinguishment		-			63,094			(63,094	)		-100.0	%
Interest income and interest expense		(68,984	)		(942,086	)		873,102			-92.7	%
Total Other Expense, Net		(30,725	)		(846,848	)		816,123			-96.4	%

Net Loss	$	(2,108,763	)	$	(3,249,541	)	$	1,140,778			-35.1	%

Grant Revenue

For the six months ended June 30, 2022 and 2021, there was $509,315 and $0, respectively, of grant revenue recognized related to qualifying expenses that were incurred and included within research and development on the condensed consolidated statements of operations.

Research and Development Expenses

Research and development expenses were $1,487,764 for the six months ended June 30, 2022, an increase of $229,641 or 18.3% compared to $1,258,123 for the six months ended June 30, 2021. The increase was primarily due to (i) increased cost on clinical trials due to increased recruitment and treatment in clinical trials, and (ii) higher insurance cost, partially offset by (iii) lower payroll and payroll taxes, and (iv) a decrease in rent ~~expense.~~and utility expenses.

	For the Three Months Ended										For the Six Months Ended
	March 31,										June 30,
	2022		2021		Increase/(Decrease)			% Change			2022		2021		Increase/(Decrease)			% Change

Operating Expenses:
Research and development:
Clinical trial and research expenses		531,691		511,580	$	20,111			3.9	%	$	1,205,985	$	977,207	$	228,778			23.4	%
Depreciation/amortization		2,164		2,162		2			0.1	%		3,929		4,324		(395	)		-9.1	%
Insurance		58,523		51,388		7,135			13.9	%		115,890		102,781		13,109			12.8	%
Payroll and taxes		67,115		72,334		(5,219	)		-7.2	%		134,475		140,040		(5,565	)		-4.0	%
Rent and utilities		11,623		17,680		(6,057	)		-34.3	%		27,485		33,771		(6,286	)		-18.6	%
Total research and development	$	671,116	$	655,144	$	15,972			2.4	%	$	1,487,764	$	1,258,123	$	229,641			18.3	%

1315

General and Administrative Expenses

General and administrative expenses were ~~$516,547~~$1,099,589 for the ~~three~~six months ended ~~March 31,~~June 30, 2022, a decrease of ~~$8,985~~$44,981 or ~~1.7%~~3.9% compared to ~~$525,532~~$1,144,570 for the ~~three~~six months ended ~~March 31,~~June 30, 2021. The decrease was primarily due to (i) lower legal fees relating to patents, ~~(ii) reduced rent and utilities cost, and (iii) lower other general and administrative cost,~~ partially offset by ~~(iv)~~(ii) higher professional fees, (iii) increased payroll and taxes, and ~~(v) higher insurance cost.~~(iv) increased other general and administration expenses.

	For the Three Months Ended											For the Six Months Ended
	March 31,											June 30,
	2022			2021		Increase/(Decrease)			% Change			2022			2021		Increase/(Decrease)			% Change

Operating Expenses:
General and administrative:
Depreciation	$	1,054		$	1,054	$	-			0.0	%	$	2,109		$	2,109	$	-			0.0	%
Directors fees		96,250			96,250		-			0.0	%		192,500			192,500		-			0.0	%
Insurance		48,218			43,566		4,652			10.7	%		92,890			85,828		7,062			8.2	%
Legal and litigation		112,534			132,015		(19,481	)		-14.8	%		238,621			348,738		(110,117	)		-31.6	%
Other general and administrative cost		22,859			31,005		(8,146	)		-26.3	%		57,335			46,588		10,747			23.1	%
Payroll and taxes		64,299			46,060		18,239			39.6	%		127,874			108,600		19,274			17.7	%
Professional fees		166,355			165,716		639			0.4	%		375,033			338,475		36,558			10.8	%
Rent and utilities		5,599			8,726		(3,127	)		-35.8	%		13,866			16,945		(3,079	)		-18.2	%
Foreign currency translation		(621	)		1,140		(1,761	)		-154.5	%		(639	)		4,787		(5,426	)		-113.3	%
Total general and administrative	$	516,547		$	525,532	$	(8,985	)		-1.7	%	$	1,099,589		$	1,144,570	$	(44,981	)		-3.9	%

Other Income/(Expense)

~~Interest expense~~Other income/(expense) decreased by ~~$458,410~~$816,123 from ~~$489,274~~($846,848) for the ~~three~~six months ended ~~March 31,~~June 30, 2021 to ~~$30,864~~($30,725) for the ~~three~~six months ended ~~March 31,~~June 30, 2022. The decrease was due to the lower interest expense costs incurred in connection with the 2017 and 2020 Notes which converted to preferred stock on June 20, ~~2021.~~2021, offset by the gain from extinguishment of debt in 2021 relating to the PPP loan forgiveness.

For the Three Months Ended
March 31,
2022 2021 Increase/(Decrease) % Change

Other Income/(Expense):
Interest income and interest expense $ (30,864 ) $ (489,274 ) $ 458,410 -93.7 %
Total Other Expenses, Net $ (30,864 ) $ (489,274 ) $ 458,410 -93.7 %

	For the Six Months Ended
	June 30,
	2022			2021			Increase/(Decrease)			% Change
Other Income/(Expense):
Research and development tax credit	$	38,259		$	32,144		$	6,115			19.0	%
Gain from extinguishment		-			63,094			(63,094	)		-100.0	%
Interest income and interest expense		(68,984	)		(942,087	)		873,103			-92.7	%
Total Other Expenses, Net	$	(30,725	)	$	(846,848	)	$	816,123			-96.4	%

Liquidity and Capital Resources

The Company’s cash, cash equivalents, and restricted cash were ~~$2,481,009~~$2,032,609 at ~~March 31,~~June 30, 2022 which includes the ~~$2,307,395~~$1,948,335 of restricted cash resulting from a grant received from the State of Tennessee, compared to $3,106,942 at December 31, 2021, which included $2,423,958 of restricted cash. The Company’s working capital deficiency was ~~$5,112,713~~$6,215,548 and $4,258,679 as of ~~March 31,~~June 30, 2022 and December 31, 2021, respectively. The condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. We have continuing net losses and negative cash flows from operating activities. In addition, we have an accumulated deficit of ~~$247,064,880~~$248,142,721 as of ~~March 31,~~June 30, 2022. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. Our financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to obtain additional financing as may be required to fund current operations.

As of ~~March 31,~~June 30, 2022, cash required for our current liabilities included approximately ~~$3,801,460~~$4,350,917 for accounts payable and accrued expenses (including lease ~~liabilities)~~liability) and a ~~$154,925~~$142,693 note payable related to our short-term financing of our commercial insurance policies. Also, if not converted prior to maturity, convertible debt in the amount of ~~$1,510,000~~$2,010,000 plus accrued interest will mature one year from the date of the notes. ~~There are no cash~~Cash requirements for long-term liabilities were $96,201 at ~~March 31,~~June 30, 2022. The Company intends to meet these cash requirements from its current cash balance and from future financing.

Management’s plans include selling our equity securities and obtaining other financing, including the 2021 financing, to fund our capital requirements and on-going operations; however, there can be no assurance we will be successful in these efforts. The condensed consolidated financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern. Significant funds will be needed to continue and complete our ongoing and planned clinical trials.

The SARS-CoV-2 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds and may also impact the volatility of our stock price and trading in our stock. Moreover, the pandemic has also significantly impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the SARS-CoV-2 pandemic will be on our business. It has the potential to adversely affect our business, financial condition, results of operations, and prospects. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development. We have taken several temporary precautionary measures intended to help ensure the well-being of our employees and contractors and to minimize disruption to our business. We considered the impact of the SARS-CoV-2 pandemic on our business and operational assumptions and estimates, and determined there were no material adverse impacts on our results of operations and financial position at ~~March 31,~~June 30, 2022.

Access to Capital

Management plans to access capital resources through possible public or private equity offerings, including the 2021 financing, equity financings, debt financings, corporate collaborations, or other means. If we are unable to raise sufficient capital, we will not be able to pay our obligations as they become due.

The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, we cannot assure you that management will be successful in implementing the Company’s business plan of developing, licensing, and/or commercializing our prescription drug product candidates. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our current and long-term requirements in 2022 and beyond. We anticipate that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Critical Accounting Estimates

The preparation of financial statements and related disclosures must be in conformity with U.S. GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which it relies are reasonably based upon information available to us at the time that it makes these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described below.

The following is not intended to be a comprehensive list of all of our accounting policies or estimates. Our accounting policies are more fully described in Note 3 –Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Stock-Based Compensation

We measure the cost of services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant. The fair value amount of the shares expected to ultimately vest is then recognized over the period for which services are required to be provided in exchange for the award, usually the vesting period. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period that the estimates are revised. We account for forfeitures as they occur.

Research and Development

Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses. We accrue for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from our external service providers. We adjust our accrual as actual costs become known.

Recently Adopted Accounting Standards

Recently adopted accounting standards are included in Note 3 – Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as special purpose entities (“SPEs”).

1617

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Inherent Limitations on Effectiveness of Controls

Even assuming the effectiveness of our controls and procedures, our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error or all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. In general, our controls and procedures are designed to provide reasonable assurance that our control system’s objective will be met, and our principal executive officer and principal financial officer has concluded that our disclosure controls and procedures are effective at the reasonable assurance level. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls in future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the ~~first~~fiscal quarter ~~of 2022~~ covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The information required by this item is incorporated by reference from Part I, Item 1. Financial Statements, Notes to Condensed Consolidated Financial Statements, Note 11.

ITEM 1A. RISK FACTORS.

There have been no material changes to the risk factors that were disclosed in the 2021 Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

2021 Financing

During the three months ended ~~March 31,~~June 30, 2022, the Company had received aggregate proceeds of ~~$50,000~~$500,000 pursuant to certain unsecured convertible notes (the “2021 Notes”). As of ~~March 31,~~June 30, 2022, the Company had cumulatively drawn down ~~$1,510,000~~$2,010,000 under the 2021 Notes.

For further details on the terms of the 2021 Notes, refer to our Form 10-K as filed with the SEC on March 29, 2022.

~~Preferred Convertible Stock~~

~~During the three months ended March 31, 2022, the Company issued 52,411 shares of Series D-1 Convertible Preferred Stock in consideration of a $150,000 investment.~~

The Company believes that such transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act (or Rule 506(b) of Regulation D promulgated thereunder) as transactions by an issuer not involving a public offering.

1718

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. Mine Safety Disclosures.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit No.		Description

~~3.1~~		Certificate of Incorporation of Provectus Biopharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 of the Company’s annual report on Form 10-K filed with the SEC on March 31, 2017).

~~3.2~~		Certificate of Elimination with respect to Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on April 5, 2022).

~~3.3~~		Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed with the SEC on June 24, 2021).

3.4**		~~Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (as amended by the Certificate of Amendment, dated March 30, 2022).~~

~~3.5~~		~~Bylaws of Provectus Biopharmaceuticals, Inc. (incorporated by reference to Exhibit 3.4 of the Company’s annual report on Form 10-K filed with the SEC on March 13, 2014).~~

31.1**		Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2**		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32***		Certification of Principal Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.

~~101.PRE~~101 PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

** Filed herewith.

*** Furnished herewith.

1819

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PROVECTUS BIOPHARMACEUTICALS, INC.

~~May 12,~~August 11, 2022	By:	/s/ Bruce Horowitz
		Bruce Horowitz
		Chief Operating Officer (Principal Executive Officer)

	By:	/s/ Heather Raines
		Heather Raines, CPA
		Chief Financial Officer (Principal Financial Officer)

1920